Citations

Clear

1446 citation(s) found for "Howard, F".

2016 American College of Rheumatology/European League Against Rheumatism Criteria for Minimal, Moderate, and Major Clinical Response in Adult Dermatomyositis and Polymyositis: An International Myositis Assessment and Clinical Studies Group/Paediatric Rheum
Rider, Lisa G. , Ruperto, Nicolino , Bayat, Nastaran, Amato, Anthony A. , Dastmalchi, Maryam, Katz, James D. , Mammen, Andrew L. , Visser, Marianne de, Ytterberg, Steven R. , Lundberg, Ingrid E. , Chung, Lorinda, Dankó, Katalin , Torre, Ignacio García‐De La , Villa, Luca, Rinaldi, Mariangela, Rockette, Howard E., Lachenbruch, Peter A., Miller, Frederick W. , Vencovský, Jiří , Rouster‐Stevens, Kelly , Huber, Adam M. , Selva-O’Callaghan, Albert , Rutkove, Seward B. , Dimachkie, Mazen M. , Olesińska, Marzena , Chung, Leland W.K. , Shinjo, Samuel Katsuyuki , Ramchandren, Sindhu , Saketkoo, Lesley Ann , Mann, H. , Aggarwal, Rohit , Erman, Brian , Feldman, Brian Michael , Oddis, Chester V. , Chinoy, Hector , Cooper, Robert G. , Fiorentino, David Franklin , Isenberg, David , Visser, Marianne de, Chung, Lorinda, Song, Yeong Wook , Mann, Heřman , Vencovsky, Jiri , Shinjo, Samuel Katsuyuki , Selva O'Callaghan, Albert , Chung, Lorinda , García-De La Torre, Ignacio , Dimachkie, Mazen M , Lundberg, Ingrid E , Pistorio, Angela

Mayo Clinic

Arthritis & Rheumatology | April 6, 2017 | Volume: 69 | Issue: 5 | Pages: 898-910

10.1002/art.40064 | PMID 28382787 Get It

ObjectiveTo develop response criteria for adult dermatomyositis (DM) and polymyositis (PM).MethodsExpert surveys, logistic regression, and conjoint analysis were used to develop 287 definitions using core set measures. Myositis experts rated greater improvement among multiple pairwise scenarios in conjoint analysis surveys, where different levels of improvement in 2 core set measures were presented. The PAPRIKA (Potentially All Pairwise Rankings of All Possible Alternatives) method determined the relative weights of core set measures and conjoint analysis definitions. The performance characteristics of the definitions were evaluated on patient profiles using expert consensus (gold standard) and were validated using data from a clinical trial. The nominal group technique was used to reach consensus.ResultsConsensus was reached for a conjoint analysis–based continuous model using absolute percent change in core set measures (physician, patient, and extramuscular global activity, muscle strength, Health Assessment Questionnaire, and muscle enzyme levels). A total improvement score (range 0–100), determined by summing scores for each core set measure, was based on improvement in and relative weight of each core set measure. Thresholds for minimal, moderate, and major improvement were ≥20, ≥40, and ≥60 points in the total improvement score. The same criteria were chosen for juvenile DM, with different improvement thresholds. Sensitivity and specificity in DM/PM patient cohorts were 85% and 92%, 90% and 96%, and 92% and 98% for minimal, moderate, and major improvement, respectively. Definitions were validated in the clinical trial analysis for differentiating the physician rating of improvement (P < 0.001).ConclusionThe response criteria for adult DM/PM consisted of the conjoint analysis model based on absolute percent change in 6 core set measures, with thresholds for minimal, moderate, and major improvement.
Changes in the Expression of Genes Associated with Intraneuronal Amyloid-β and Tau in Alzheimer's Disease
Fujimura, Robert K., Reiner, Teresita, Ma, Fangchao , Phillips, Virginia , Pozas, Alicia de las, Dickson, Dennis W. , Roos, Bernard A., Howard, Guy A., Perez‐Stable, Carlos , Dickson, Dennis W

Mayo Clinic

Journal of Alzheimer's Disease | April 5, 2017 | Volume: 19 | Issue: 1 | Pages: 97-109

10.3233/jad-2010-1216 | PMID 20061629 Get It

Characterization of relative biological effectiveness for conventional radiation therapy: a comparison of clinical 6 MV X-rays and 137Cs
Howard, Michelle E. , Beltran, Chris , Herman, Michael , Sarkaria, Jann, Herman, Michael G., Sarkaria, Jann N. , Beltran, Chris J

Mayo Clinic

Journal of Radiation Research | April 5, 2017 | Volume: 58 | Issue: 5 | Pages: 608-613

10.1093/jrr/rrx018 | PMID 28444207 Get It

ABSTRACT Various types of radiation are utilized in the treatment of cancer. Equal physical doses of different radiation types do not always result in the same amount of biological damage. In order to account for these differences, a scaling factor known as the relative biological effectiveness (RBE) can be used. 137Cesium (137Cs) has been used as a source of radiation in a significant body of radiation therapy research. However, high-energy X-rays, such as 6 MV X-rays, are currently used clinically to treat patients. To date, there is a gap in the literature regarding the RBE comparison of these two types of radiation. Therefore, the purpose of this study was to investigate the RBE of 137Cs relative to that of 6 MV X-rays. To determine the RBE, five cell lines were irradiated [Chinese hamster ovary (CHO); human lung adenocarcinoma (A549); human glioma (U251); human glioma (T98); and human osteosarcoma (U2OS)] by both types of radiation and assessed for cell survival using a clonogenic assay. Three of the five cell lines resulted in RBE values of ~1.00 to within 11% for all survival fractions, showing the physical and biological dose for these two types of radiation were equivalent. The other two cell lines gave RBE values differing from 1.00 by up to 36%. In conclusion, the results show the range in biological effect seen between cell lines, and therefore cell type must be considered when characterizing RBE.
Comparative effectiveness of tumor response assessment methods: Standard-of-care versus computer-assisted response evaluation.
Florez, Edward , Sirous, Reza , Lirette, Seth T. , Griswold, Michael , Wang, Zhen J. , Bieszczad, Jacob, Cox, Kelly , Goenka, Ajit H. , Howard-Claudio, Candace M, Sanyal, Rupan , Henagen, J. Clark, Storrs, Judd , Allen, Brian C. , Remer, Erick M. , Howard, Candace M. , Kang, HyunSeon Christine , Nandwana, Sadhna B. , Shinagare, Atul Bhanudas , Davenport, Matthew S. , Rini, Brian I. , Smith, Andrew D. , Storrs, Judd M , Lirette, Seth

Mayo Clinic

Journal of Clinical Oncology | March 29, 2017 | Volume: 35 | Issue: 6_suppl | Pages: 432-432

10.1200/jco.2017.35.6_suppl.432 Get It

432 Background: In clinical trials and clinical practice, tumor response assessment with computed tomography (CT) defines critical end points in patients with metastatic disease treated with systemic agents. Methods to reduce errors and improve efficiency in tumor response assessment could improve patient care. Methods: Eleven readers from 10 different institutions independently categorized tumor response according to three different therapeutic response criteria using paired baseline and initial post-therapy CT studies from 20 randomly selected patients with metastatic renal cell carcinoma treated with sunitinib as part of a completed phase III multi-institutional study. Images were evaluated with a manual tumor response evaluation method (standard-of-care) and with computer-assisted response evaluation (CARE) that included stepwise guidance, interactive error-identification and correction methods, automated tumor metric extraction, calculations, response categorization, and data/image archival. A cross-over design, patient randomization, and two-week washout period were used to reduce recall bias. Comparative effectiveness metrics included error rate and mean patient evaluation time. Results: The standard-of-care method was on average associated with one or more errors in 30.5% (6.1/20) of patients while CARE had a 0.0% (0.0/20) error rate (p<0.001). The most common errors were related to data transfer and arithmetic calculation. In patients with errors, the median number of error types was 1 (range 1-3). Mean patient evaluation time with CARE was twice as fast as the standard-of-care method (6.4 vs. 13.1 minutes, p<0.001). Conclusions: Computer-assisted tumor response evaluation reduced errors and time of evaluation, indicating better overall effectiveness than manual tumor response evaluation methods that are the current standard-of-care.
Pertuzumab plus trastuzumab for HER2-positive metastatic urothelial cancer (mUC): Preliminary data from MyPathway.
Hurwitz, Herbert I. , Hainsworth, John D. , Bose, Ron , Burris, Howard A. , Guo, Shuangli, Yoo, Bongin, Beattie, Mary, Tayama, Darren, Bryce, Alan H. , Kurzrock, Razelle , Meric‐Bernstam, Funda , Spigel, David R. , Swanton, Charles , Sweeney, Christopher J.

Mayo Clinic

Journal of Clinical Oncology | March 29, 2017 | Volume: 35 | Issue: 6_suppl | Pages: 348-348

10.1200/jco.2017.35.6_suppl.348 Get It

348 Background: Patients (pts) with mUC have few treatment options beyond the second-line setting. HER2 gene amplification has been reported in a minority of pts with UC, but there have been anecdotal reports of the activity of HER2-targeted agents. MyPathway is a multi-basket study evaluating the efficacy and safety of targeted therapies in non-indicated tumor types harboring relevant molecular alterations. We present preliminary data for pts with HER2-positive mUC receiving HER2-targeted treatment with pertuzumab + trastuzumab. Methods: MyPathway (NCT02091141) is an open-label, multicenter, phase IIA study. Pts in this subset analysis had refractory mUC with HER2 amplification or putative activating mutations by gene sequencing, FISH, or IHC. Pts received standard doses of pertuzumab + trastuzumab without chemotherapy until disease progression or unacceptable toxicity. The primary endpoint is investigator-assessed overall response rate (RECIST v1.1). Results: As of July 31, 2016, 12 pts with platinum-resistant HER2-positive mUC (HER2-amplified, n=9; HER2-mutated, n=3) have been enrolled. At a median follow-up of 5.4 (range 0.9–14.5) mos, 1 pt had complete response (CR, ongoing at 12.5 mos), 2 had partial responses (PR; duration of response, 3.7 and 5.5 mos), and 2 had stable disease (SD) for >4 mos (Table). Safety was consistent with the product labels. Conclusions: Preliminary results indicate that the combination of pertuzumab + trastuzumab has activity in previously treated HER2-amplified mUC, including a durable CR in a pt with peritoneal metastases. Accrual to MyPathway is ongoing. Clinical trial information: NCT02091141. [Table: see text]
Associations of physical activity with survival and progression in metastatic colorectal cancer: Results from CALGB 80405 (Alliance).
Niedzwiecki, Donna , Sato, Kaori , Fuchs, Charles S. , Lenz, Heinz‐Josef , Innocenti, Federico , Fruth, Briant, Blarigan, Erin Van, O’Neil, Bert H. , Polite, Blasé N. , Höchster, Howard S. , Atkins, James N., Goldberg, Richard M. , Blanke, Charles D. , Guercio, Brendan J. , Venook, Alan P. , Zhang, Sui , Blarigan, Erin L. Van , Shaw, James Edward , Mayer, Robert J. , Bertagnolli, Monica M. , Meyerhardt, Jeffrey A. , Niedzwiecki, Donna

Mayo Clinic

Journal of Clinical Oncology | March 21, 2017 | Volume: 35 | Issue: 4_suppl | Pages: 659-659

10.1200/jco.2017.35.4_suppl.659 Get It

659 Background: Regular physical activity (PA) is associated with reduced risk of recurrence and mortality in non-metastatic colorectal cancer. Its influence on patients with metastatic colorectal cancer (mCRC) is largely unexplored. Methods: 1231 patients participating in CALGB 80405 (first-line phase III chemotherapy trial for mCRC) completed questionnaires that included self-report on PA at time of chemotherapy initiation and total metabolic equivalent task (MET)-hours/week were determined based on responses. The primary endpoint of the clinical trial and this companion study was overall survival (OS), with progression-free survival (PFS) as a secondary endpoint. To minimize confounding by poor and rapidly declining health, we excluded patients who experienced progression or died within 60 days of activity assessment and adjusted for known prognostic factors, comorbid illness, and weight loss over the previous six months. Results: Compared with patients engaged in less than three MET-hours/week of PA, patients engaged in 18 or more MET-hours/week experienced an adjusted hazard ratio for OS of 0.81 (95% CI 0.67 to 0.98, P for trend 0.03) and for PFS of 0.84 (95% CI 0.71 to 1.00, P for trend 0.03). Greater nonvigorous PA and walking duration were both associated with improved OS ( P for trend 0.01 and 0.04, respectively). Conclusions: In mCRC patients from CALGB 80405, greater total PA was associated with improved PFS and OS, while greater walking duration and non-vigorous PA were associated with reduced risk of all-cause mortality. Support: U10CA180821, U10CA180882. ClinicalTrials.gov ID: NCT00265850 [Table: see text]
Potentially preventable readmissions after complex cancer surgery: Analysis of the national readmissions dataset.
Raoof, Mustafa , Wilson, Lori , Wasif, Nabil , Zafar, Syed Nabeel , Shah, Adil A.

Mayo Clinic

Journal of Clinical Oncology | March 21, 2017 | Volume: 35 | Issue: 4_suppl | Pages: 109-109

10.1200/jco.2017.35.4_suppl.109 Get It

109 Background: Hospital readmissions following surgery are a focus of quality improvement efforts nationwide. Although some reflect appropriate care, others are potentially preventable readmissions (PPRs). We aim to describe the burden, timing, and factors associated with PPRs after complex cancer surgery. Methods: The National Readmissions Dataset (2013) was used to select patients undergoing a complex oncologic resection (defined as esophagectomy/gastrectomy, hepatectomy, pancreatectomy, colorectal resection, lung resection, and cystectomy). All Readmissions occurring within 30 days from discharge were analyzed. Causes for readmissions were categorized in eleven diagnostic groups and tabulated. ICD-9 primary diagnosis codes were reviewed to identify PPRs. Logistic regression analyses were used to identify demographic, clinical and hospital factors associated with PPRs. Results: We analyzed 60,970 patients with 92,260 admissions. A 30 day readmission occurred in 14% of patients, and was highest following cystectomy (25%) and lowest for lung resections (9%). Of all readmissions 82% were deemed to be PPRs. Half of PPRs occurred within the first 10 days of discharge. Infections, gastrointestinal complications and respiratory conditions accounted for 59% of PPRs. Other common causes included dehydration/electrolyte deficiencies (11%), exacerbation of comorbidity (9.2%), bleeding (5%), thromboembolism (3.5%), and wound complications (3.2%). Factors associated with an increased likelihood of PPRs include Medicaid compared with private insurance (OR 1.24, 95%CI 0.8-1.7), higher comorbid conditions (OR 1.44, 95%CI 1.32, 1.59), and discharge to a facility (OR 1.9, 95%CI 1.7-2.1). Patients with a prolonged hospital stay or a major complication during the index admission had a 34% (OR 1.34, 95%CI 1.3-1.4), and 64% (OR 1.64, 95%CI 1.5-1.7) higher likelihood of a PPR respectively. Conclusions: Most 30 day readmissions after complex cancer surgery are potentially preventable and occur within 10 days of discharge. We identify common causes of readmission and high risk populations to help physicians, administrators and policy makers develop strategies to decrease PPRs.
Initial results of CALGB 80803 (Alliance): A randomized phase II trial of PET scan-directed combined modality therapy for esophageal cancer.
Niedzwiecki, Donna , Ye, Xing , Meyers, Michael O. , Mitchell-Richards, Kisha, Boffa, Daniel J., Höchster, Howard S. , Crane, Christopher H. , Ilson, David H. , Goodman, Karyn A. , Hall, Nathan C. , Bekaii‐Saab, Tanios , Frankel, Wendy L. , Venook, Alan P. , O’Reilly, Eileen M. , Niedzwiecki, Donna

Mayo Clinic

Journal of Clinical Oncology | March 21, 2017 | Volume: 35 | Issue: 4_suppl | Pages: 1-1

10.1200/jco.2017.35.4_suppl.1 Get It

1 Background: To determine whether changing chemotherapy (CT) during pre-op chemoradiation (CRT) based on response to induction CT by 18F-fluoro-deoxyglucose PET imaging can lead to improved pathologic complete response (pCR) in patients (pts) with resectable esophageal and gastroesophageal junction (GEJ) adenocarcinomas. Methods: 257 eligible pts were enrolled, underwent baseline PET scan, and were randomized to one of 2 induction CT arms: Modified FOLFOX-6 (oxaliplatin, leucovorin, 5-FU), days 1, 15, 29 or Carboplatin/Paclitaxel (CP), days 1, 8, 22, 29. Repeat PET was performed days 36-42; change in max standardized uptake value (SUV) from baseline was assessed. PET non-responders (≤35% decrease in SUV – PET-NR) crossed over to alternative CT regimen during CRT (50.4Gy/28 fractions). PET responders (>35% decrease in SUV – PET-R) continued on same CT during CRT. Pts underwent surgery 6 wks post-CRT. Pts evaluable if had surgery, disease progression (PD), death due to disease, were unresectable or had adverse event (AE). Primary endpoint was pCR in PET-NR who crossed over to alternative CT (expected 5% under H0 to 20% under Ha). Results: Pre-audit PET response data after induction CT and pCR rates after CRT and surgery are shown in the table. For PET-NR who crossed over to alternative CT during CRT, pCR was 15.6%; 95% CI (0.08, 0.26). Conclusions: Efficacy criteria were met for an improvement in pCR rates among pts who were PET-NR after induction CT and received alternative CT during CRT for esophageal and GEJ adenoca. Pts receiving induction and concurrent CP had an unexpectedly low pCR. Support: U10CA180821, U10CA180882 Clinical trial information: NCT01333033. [Table: see text]
Abstract P6-12-04: Phase 1 study of the antibody-drug conjugate (ADC) SGN-LIV1A in patients with heavily pretreated metastatic breast cancer
Forero‐Torres, Andres , Specht, Jennifer M. , Weise, Amy, Burris, Howard A. , Liu, Ming, Krop, Ian E. , Mita, Monica , Modi, Shanu , Miller, Kathy D. , Pusztai, Lajos , Kostic, Aleksandar David , Li, Michael , Specht, Jennifer

Mayo Clinic

Cancer Research | March 1, 2017 | Volume: 77 | Issue: 4_Supplement | Pages: P6-12-04-P6-12-04

10.1158/1538-7445.sabcs16-p6-12-04 Get It

Abstract Background LIV-1, a transmembrane protein and downstream target of STAT3, is highly expressed in breast cancer cells. It is associated with lymph node involvement and metastatic progression. SGN-LIV1A is an anti-LIV-1 antibody conjugated via a protease-cleavable linker to monomethyl auristatin E (MMAE). Upon binding to cell-surface LIV-1, SGN-LIV1A is internalized and releases MMAE, which binds to tubulin and induces G2/M arrest and apoptosis. Methods This is an ongoing, phase 1 dose-escalation study evaluating safety, tolerability, pharmacokinetics, and antitumor activity of SGN-LIV1A (q3 wks IV) in women with LIV-1-positive, unresectable, locally advanced or metastatic breast cancer (LA/MBC) (NCT01969643). Patients (pts) with measurable disease and ≥2 prior cytotoxic regimens for LA/MBC were eligible. Pts with ≥Grade 2 neuropathy were excluded. Response was assessed per RECIST v1.1; pts with stable disease (SD) or better could continue treatment until disease progression or intolerable toxicity. At completion of dose escalation in hormone receptor-positive/HER2-negative (HR+/HER2–) and triple-negative (TN) pts, expansion cohorts were opened to further evaluate safety and antitumor activity of monotherapy in TN pts and combination therapy with trastuzumab (Tz) in HER2-positive (HER2+) pts. Pre- and post-treatment tumor biopsies were done to evaluate LIV-1 expression and other correlative endpoints. Results To date, 39 pts (18 HR+/HER2–, 21 TN) have received a median of 3 cycles (range, 1–10) of SGN-LIV1A monotherapy at doses of 0.5–2.8 mg/kg. Median age was 57 yrs (range, 33–79). At baseline, pts had a median of 4 prior cytotoxic regimens for LA/MBC (range, 2–8); 36 had visceral disease and 25 had bone involvement. No dose-limiting toxicities (DLT) occurred in 19 DLT-evaluable pts; maximum tolerated dose was not exceeded at 2.8 mg/kg. Treatment-emergent adverse events (AEs) reported in ≥30% of pts were: fatigue (64%), nausea (54%), alopecia (46%), decreased appetite (41%), constipation (39%), neutropenia (33%), and vomiting (31%). Peripheral neuropathy was reported in 9 pts (23%). Most AEs were Grade 1/2, except neutropenia (all ≥Grade 3). Four pts discontinued treatment due to AEs (acute respiratory distress syndrome, nausea, pneumonia, tachycardia). In dose escalation, modest activity was observed in 17 efficacy evaluable (EE) HR+/HER2- pts, with a disease control rate (DCR) of 59% (10 SD), including 1 pt with SD≥24 wks. Among the 17 EE TN pts (dose escalation plus cohort expansion), the overall response rate (ORR) was 41% (7 PR), DCR was 82% (7 PR, 7 SD) and clinical benefit rate (CBR=OR+SD≥24 wks) was 53% (9 pts). For TN pts, median PFS was 17.1 wks (95% CI: 6.0, 18.4); 6 pts remain on treatment. Of 281 MBC tumor samples evaluated for LIV-1, 93% were positive; 81% had moderate-to-high expression (H-score ≥100). Conclusions LIV-1 is expressed in almost all MBC tumors. SGN-LIV1A monotherapy has been generally well tolerated and shown encouraging antitumor activity in heavily pretreated TN MBC, with a PR rate of 41% and a CBR at ≥24 wks of 53%. Response duration data continue to evolve. Enrollment continues in the TN monotherapy expansion cohort and the HER2+ combination cohort with Tz. Citation Format: Forero-Torres A, Modi S, Specht J, Miller K, Weise A, Burris III H, Liu M, Krop I, Pusztai L, Kostic A, Li M, Mita M. Phase 1 study of the antibody-drug conjugate (ADC) SGN-LIV1A in patients with heavily pretreated metastatic breast cancer [abstract]. In: Proceedings of the 2016 San Antonio Breast Cancer Symposium; 2016 Dec 6-10; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2017;77(4 Suppl):Abstract nr P6-12-04.